ASCO
Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer
Premium
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.
The company reported positive data from the Phase II RAGNAR study, in which Balversa showed activity across 14 different tumor types.
The companies have expanded their partnership to include GE's Fabric technology as they seek to predict response to metastatic non-small cell lung cancer therapies.
Yondelis Fails to Improve Survival in BRCA1/2-Mutant Ovarian Cancer in Phase III ASCO Study
Counter to a prior study, recurrent ovarian cancer patients with BRCA1/2 mutations or a BRCAness phenotype did not benefit on single-agent Yondelis versus chemo.
Biomarker-Defined Subset of Early Breast Cancer Patients Can Avoid Radiation, ASCO Data Show
The LUMINA trial showed that a molecularly defined subset of breast cancer patients over age 55 had an extremely low local recurrence rate when they omitted radiation.